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Two populationsor[‘H]CGP 12177 binding sitesexist in rat interscapular brownadiposc tissue (IBAT) plasma membranes. The majority of binding 
sites nre of low affinity with a Kd of 31 nM, a value in close agreement with that for the Kd of [‘H]CGP 12177 bmding to a cloned rat&adrenergic 
receptor (AR) expressed in CHO cells (44 nM). Competition binding studies dcmonstrdle that the Ki values of the cloned rat Pa-AR and of the 
low affinity sites in IBAT are 45 and 29 nM, respectively. for DRL 37344 and 1.4and l.OpM, for (-)~propranolol. These findings trongly suggest 
that the low uflinity vH]CGP 12177 binding site measured in IBAT plnsma membranes represents he atypical &-AR in this tissue. 
Atypical &tdrcncrgic receptor; Drown fat; Binding 
1. 1NTRODUCTION 
Brown adipose tissue (BAT) is the main effector of 
cold- and diet-induced thermogenesis n rodents [1,2]. 
The metabolism of this tissue is primarily regulated by 
norepinephrine released from sympathetic nerves which 
acts through /I-adrenergic receptors (-AR) [3,4]. Al- 
thoughp, and ,&ARs are present in BAT, considerable 
evidence has suggested that the /?-AR which mediates 
lipolysis in this tissue displays pharmacological 
properties inconsistent with the PI/,&AR subclassifica- 
tion scheme [SJ. Recently, we isolated and characterized 
a cDNA from a rat interscapular BAT (IBAT) library 
which encodes a &AR that displays low affinity for 
classical P-AR antagonists uch as propranolol and al- 
prenolol, and high affinity for thermogenic /?-AR 
agonists such as BRL 37344 [6]. The rank order of 
agonist potency for stimulation of CAMP accumulation 
in CHO cells transfected with the rat IBAT ,&AR 
correlates with that previously reported for stimulation 
of lipolysis in rat IBAT [S]. 
It has been difficult to directly measure the&AR in 
BAT in radioligand binding studies because the avail- 
,able radiolabeled antagonists display a markedly lower 
affinity for the Pa-AR than for /I,- and &ARs. It was 
shown that the large component of non-specific binding 
of [“sI]iodocyanopindolol (ICYP) to BAT plasma 
membranes at the high concentrations necessary to 
detect specific binding to the &AR prevented accurate 
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characterization of the binding parameters of this re- 
ceptor [7,8], The hydrophilic compound CGP 12177 [I)], 
generally classified as a P-AR antagonist, was recently 
found to behave as a thermogenic agonist in BAT [lo]. 
Blum-Kaelin et al. [l 11 used [3H]CGP 12177 to demon- 
strate the existence of two populations of binding sites 
in rat IBAT plasma membranes, one with a high affinity 
which was presumed to represent the/?,/&A.R subtypes 
present in this tissue and one with a low affinity, 
presumed to represent the P3-AR. 
The aim of this study was to compare the binding 
characteristics of [‘H]CGP 12177 binding to ,&ARs in 
isolated IBAT piasma membranes and in CHO cells 
transfected with the rat j3-AR in order to gain more 
information on the identity of the two populations of 
tH]CGP 12 177 binding sites described in IBAT plasma 
membranes. Herein, we describe conditions that allow 
for the measurement of specific [3H]CGP 12177 binding 
to the jIJ-AR in IBAT. 
2. MATERIALS AND METHODS 
All organic and inorganic hemicals were of analytical or molecular 
biology grade. [“H]CGP 12177 (30 Cimmol) was purchased from 
Artiersham. CMO~KI cells were from the American Type Culture Col- 
lection. Tissue culture reagents were from GibcolBRL. BRL 37344 
was a gift from Beccham Pharmaceuticals (Epsin. UK). Spmguc- 
Dawlcy mole rats (9 weeks old) were kept at room temperature (about 
21°C) with 12 h of illumination per day and fed ad libitum with 
Provimi Lacta chow (Cossonay, Switzerland). The IBAT plasma 
membranes were prepared from pools of IBAT from six rats as previ- 
ously described [12]. Protein concentrations were determined by the 
method of Lowry ct al. [I 9. 
The cloning of the rat cDNA encoding thcp,-AR, its stable expres- 
sion in CHO.KI cells and the preparation of CHO-KI cell membrane 
fractions have been described 161. 
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Fig. 1. Specific binding of[3H]CGP 1 ?I 77 to IBAT plasma membranes 
as a function of increasing concentrations of the ligand. The results 
Fig. 2. Displacement of [‘H]CGP 12177 (50 nM) binding IO IBAT 
illustrated arc from one rcprcscntative experiment and are expressed 
plasma membranes by increasing concentrations of BRL 37344 (+) or 
in fmol of l&and bound per mg of plasma membrane proteins. (Inset) 
(-).propranolol (v). The results illustrated are from one rcprescnta- 
live experiment and are expressed as percent of the specific binding 
value in the absence of competitor. Scatchard analysis of the data of the rcprescntativc experiment. 
In radioligand binding studies, mcmbrancs wcrc incubated for 30 
min at 37OC in Tris-HCI 50 mM. pH 7.4. MgClz IO mM (total 
volume 0.5 ml) containing GTP 50 PM and the indicated amount(s) 
of [“H]CGP 12177. The binding of the radioligand to the membranes 
was determined by ftltration using a Brandcl M-24 R apparatus. Spc- 
cific binding was defined as the difference berwecn the total binding 
obtained in the absence of competing ligand and the non-specific 
binding obtained in the presence of (-)-propranolol (100 PM). Bach 
assay was performed in duplicate. 
3. RESULTS AND DISCUSSION 
Fig. 1 shows the radioligand binding studies per- 
formed on rat IBAT plasma membranes. Scatchard 
analysis of saturation isotherms indicate the presence of 
two populations of [‘H]CGP 12177 binding sites. Their 
& values were found by a non-linear egression analysis 
using the LIGAND program [141 to be 0.64 and 3 1 nM 
(Table I). These values are in excellent agreement with 
those reported by Blum-Kaelin et al. [l l] of 0.42 and 45 
nM obtained from similar experiments. The Kd value 
for [3H]CGP 12177 binding to the rat IBAT ,f13-AR in 
transfected CM0 cell membranes was 44 nM (Table I), 
a value essentially identical to that for the low affinity 
binding site in IBAT plasma membranes. Our data are 
-7 .6 -5 -4 -3 -2 
LOQ Dose [tZompetltor] (M) 
consistent with the hypothesis that the population of 
low affinity binding sites in IBAT represents the&-AR 
whereas the population of high afBnity sites represents 
the /&I&-AR subtypes. 
As summarized in Table I, the low affinity [3H]CGP 
12177 binding sites in IBAT plasma membranes re- 
present 70% of the total [3H]CGP 12177 binding sites in 
this tissue. The distribution of low and high affinity sites 
in IBAT correlates with the relative proportion of /Ij- 
AR- and ~,/j?z-AR-specific mRNA, respectively, in 
IBAT [6]. Together, these data suggest hat the/$,-AR, 
which displays low affinity for [3H]CGP 12177, re- 
presents the predominant P-AR subtype in IBAT. 
In order to examine the binding of other @-AR 
ligands to the IBAT &ARs, competition studies with 
[3H]CGP 12177 and BRL 37344 or (-)-propranolol 
were performed (Fig. 2). Ki values for BRL 37344 and 
propranolol binding to the high affinity 13H]CGP 12177 
sites in IBAT were calculated by an Hofstee analysis 
using the LIGAND program [14] to be 12.2 and 0.003 
PM, respectively (Table 11). These values are similar to 
those reported for the binding of these compounds to 
p,- or ,&ARs [7,11]. The Ki value for propranolol bind- 
ing to the high affinity [3H]CGP 12177 sites in IBAT is 
Table I 
[‘H]CGP 12177 binding to IBAT and CHO-RI B, cell membranes 
IBAT 
CHO-KI /3> 
High affinity binding sites 
& (nM) &,,, (fmol per ms) 
0.64 4 0.17 (3) 330 t 44 (3) 
Low afinity binding sites 
h; (nM) B,, (fmol per mg) 
31 f 9 (3) 770 P 85 (3) 
44 f 4 (3) I I80 + 140 (3) 
- 
The results are the mean 2 S.E.M. of the number of experiments in parcnthcses. i olation of 
cell membranes and assays are described in Materials and Methods. Concentrations of [‘HICGP 
12177 used varied from 125 pM to 100 nM. The Kd are expressed in nM and the Btik in fmol 
of [‘H]CGP I21 77 bound per mg of membrane proteins. 
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Displacement oT[~H]CGP 12177 binding to IBAT and CHO-Kl & cell membranes by (-)-propranolol and BRL 37344 
High affinity binding sites Low affinity binding sites 
K, of (-)-propranolol WM) Ki of BRL 37344 bM) Kr of (-)-propranolol @M) Ki OF BRL 37344 WM) 
IBAT 0.003 f 0.001 (3) 12.1 2 3.6 (3) 1 .o 2 0.1 (3) 5.029 t O.fJOS (3) 
CHO-KI ,& - I.4 -c I.7 (4) 0.045 f 0.009 (5) 
The results are the mean I S.E.M. of the number ofexperiments in parentheses. I olation ofcell membranes and assays arcdescribed 
in Materials and Methods. The concentration of [“H]CGP 12177 used was 50 nM. The results are expressed in inhibition constants 
(Ki) in fiM. 
4100-fold lower than that for BRL 37344. In contrast, 
the Ki of BRL 37344 (0.029 PM) binding to the low 
affinity [“H]CGP 12177 site in IBAT is 34-fold lower 
than that for propranolol (1.0 PM). The Ki values for 
BRL 37344 and propranolol binding to the low affinity 
[3H]CGP 12 177 sites in IBAT membranes are very sim- 
ilar to those obtained in competition experiments with 
membranes prepared from CHO cells expressing the rat 
&AR (0.045 and I .4 ,uM, respectively). These findings 
confirm that the low affmity t3H]CGP 12177 binding 
site in IBAT plasma membranes represents the &-AR 
subtype, whereas the high affinity binding site re- 
presents fi,- and /J,-ARs. 
In summary, using i3H]CGP 12177 as a radioligand, 
the &AR subtype of rat IBAT plasma membranes can 
be directly measured. This can be accomplished by 
using a concentration of [3H]CGP 12177 equal to the I& 
of the B-AR in the absence or presence of a concentra- 
tion of BRL 37344 which would displace only the bind- 
ing to the&-AR (IO PM). Specific binding to the &AR 
is then defined as the difference between total binding 
obtained in the absence of competing ligand and the 
binding obtained in the presence of BRL 37344. Specific 
binding to /3,$?,-AR subtypes in IBAT can be quan- 
titated as the difference between t3H]CGP 12 I77 in the 
presence of 10 PM BRL 37344 and in the presence of 
100 FM (-)-propranolol, a concentration sufficient to 
displace [3W]CGP 12177 binding to all P-AR subtypes 
in IBAT membranes. 
It has been suggested that the population of low aftin- 
ity binding sites in IBAT mediates the metabolic effects 
of CGP 12177 [lO,ll]. This would imply that CGP 
12177 exerts its effects on IBAT metabolism only via the 
&AR. More studies are necessary to determine the 
respective biological importance of B-AR subtypes in 
the response of BAT to catecholamines. 
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